Add office photos
Employer?
Claim Account for FREE
Johnson & Johnson
4.0
based on 1.5k Reviews
Video summary
Company Overview
Associated Companies
Company Locations
Working at Johnson & Johnson
Company Summary
Johnson & Johnson operates in the healthcare sector, focusing on innovation to enhance global health outcomes through consumer products and medical solutions.
Overall Rating
4.0/5
based on 1.5k reviews
3% above
industry average
Highly rated for
Company culture, Salary, Work-life balance
Critically rated for
Promotions
Work Policy
Hybrid
59% employees reported
Monday to Saturday
48% employees reported
Flexible timing
69% employees reported
Within city
38% employees reported
View detailed work policy
Top Employees Benefits
Job/Soft skill training
115 employees reported
Health insurance
100 employees reported
Office gym
59 employees reported
Office cab/shuttle
52 employees reported
View all benefits
About Johnson & Johnson
Founded in1957 (68 yrs old)
India Employee Count1k-5k
Global Employee Count1 Lakh+
HeadquartersNew Brunswick, New Jersey, United States (USA)
Office Locations
Websitejnj.in
Primary Industry
Other Industries
Are you managing Johnson & Johnson's employer brand? To edit company information,
claim this page for free
View in video summary
Caring for the world, one person at a time inspires and unites the people of Johnson & Johnson. We embrace innovation—bringing ideas, products, and services to life to advance the health and well-being of people around the world. We believe in collaboration, and that has led to breakthrough after breakthrough, from medical miracles that have changed lives, to the simple consumer products that make every day a little better. Our over 125,000 employees in 60 countries are united in a common mission: to help people everywhere live longer, healthier, happier lives.
Report error
Managing your company's employer brand?
Claim this Company Page for FREE
Brands of Johnson & Johnson
Medical Devices
4.1
• 19 reviews
Johnson & Johnson Ratings
based on 1.5k reviews
Overall Rating
4.0/5
How AmbitionBox ratings work?
5
784
4
361
3
152
2
67
1
99
Category Ratings
3.9
Company culture
3.9
Salary
3.9
Work-life balance
3.9
Skill development
3.8
Work satisfaction
3.7
Job security
3.3
Promotions
Johnson & Johnson is rated 4.0 out of 5 stars on AmbitionBox, based on 1.5k company reviews. This rating reflects a generally positive employee experience, indicating satisfaction with the company’s work culture, benefits, and career growth opportunities. AmbitionBox gathers authentic employee reviews and ratings, making it a trusted platform for job seekers and employees in India.
Read more
Gender Based Ratings at Johnson & Johnson
based on 1.4k reviews
3.8
Rated by 250 Women
Rated 3.7 for Work-life balance and 3.7 for Company culture
4.1
Rated by 1.1k Men
Rated 4.0 for Company culture and 4.0 for Skill development
Work Policy at Johnson & Johnson
based on 137 reviews in last 6 months
Hybrid
59%
Work from office
36%
Permanent work from home
5%
Johnson & Johnson Reviews
Top mentions in Johnson & Johnson Reviews
+ 5 more
Compare Johnson & Johnson with Similar Companies
 |  Change Company |  Change Company |  Change Company | |
|---|---|---|---|---|
Overall Rating | 4.0/5 based on 1.5k reviews | 4.0/5 based on 2.7k reviews | 3.7/5 based on 2.9k reviews | 4.4/5 based on 2.3k reviews |
Highly Rated for | Skill development Work-life balance Salary | Job security Work-life balance Company culture | Job security | Skill development Work-life balance Salary |
Critically Rated for | Promotions | Promotions | Promotions Salary |  No critically rated category |
Primary Work Policy | Hybrid 59% employees reported | Hybrid 84% employees reported | Work from office 50% employees reported | Work from office 83% employees reported |
Rating by Women Employees | 3.8 Good rated by 250 women | 4.1 Good rated by 757 women | 3.8 Good rated by 898 women | 4.4 Good rated by 858 women |
Rating by Men Employees | 4.1 Good rated by 1.1k men | 4.0 Good rated by 1.8k men | 3.6 Good rated by 1.8k men | 4.2 Good rated by 1.1k men |
Job security | 3.7 Good | 4.1 Good | 3.8 Good | 4.1 Good |
View more
Johnson & Johnson Salaries
Johnson & Johnson salaries have received with an average score of 3.9 out of 5 by 1.5k employees.
District Manager
(130 salaries)
Unlock
₹6 L/yr - ₹13.5 L/yr
Medical Representative
(114 salaries)
Unlock
₹1.8 L/yr - ₹6 L/yr
Associate District Manager
(111 salaries)
Unlock
₹4 L/yr - ₹9.5 L/yr
Field Manager
(104 salaries)
Unlock
₹10 L/yr - ₹20.2 L/yr
Area Sales Manager
(79 salaries)
Unlock
₹6.5 L/yr - ₹27.4 L/yr
Area Business Incharge
(71 salaries)
Unlock
₹7.7 L/yr - ₹17 L/yr
Sales Executive
(69 salaries)
Unlock
₹1.2 L/yr - ₹6.6 L/yr
Senior Sales Officer
(66 salaries)
Unlock
₹7.8 L/yr - ₹15.9 L/yr
Data Analyst
(66 salaries)
Unlock
₹3 L/yr - ₹11.8 L/yr
Medical Sales Representative
(66 salaries)
Unlock
₹2.4 L/yr - ₹6 L/yr
Johnson & Johnson Interview Questions
A Territory Business Manager was asked Q. What are the salary packages?
A Modular Kitchen Designer was asked 12mo agoQ. How much experience certifcate
A RSR was asked Q. Are you flexible for transfer?
A Quality Manager was asked Q. What is your role in handling QMS activities?
A Planning Analyst was asked Q. Explain Safety Stock in brief.
Johnson & Johnson Jobs
Popular Skills Johnson & Johnson Hires for
Current Openings
Johnson & Johnson News
View all
Kenvue Is Considering Selling Some Brands, Reuters Reports
- Kenvue Inc., originally part of Johnson & Johnson, is considering selling some of its skincare and beauty brands like Clean & Clear, Maui Moisture, and Neostrata.
- The company aims to retain bigger brands like Neutrogena and Aveeno amidst pressure from shareholders, including activist investors like Starboard Value LP and Toms Capital.
- Activists argue that Kenvue trades at a discount to competitors despite owning top-tier brands in skincare, home care, and over-the-counter drugs like Tylenol.
- Kenvue's shares have remained stagnant since its 2023 IPO, contrasting with the S&P 500 Index's 48% increase over the same period.
- The decision to sell certain brands is part of Kenvue's strategic response to shareholder demands and market positioning.
- Kenvue's potential sale of brands aligns with efforts to enhance shareholder value and address market competitiveness.
Bloomberg Quint | 13 Jun, 2025
J&J reports positive Monarch robotic bronchoscopy data
- Johnson & Johnson MedTech reported positive results from a study of its Monarch platform for robotic bronchoscopy procedures, showing a high success rate in reaching and biopsying lung nodules with a good safety profile.
- The study, TARGET, involved 679 patients across 21 global sites and demonstrated a diagnostic yield of 83.2% with Monarch reaching the lesions in 98.7% of cases.
- Investigators identified factors associated with higher diagnostic yield and recognized robotic-assisted bronchoscopy as a safe and effective option that could elevate the standard of care for patients.
- Johnson & Johnson is committed to advancing innovation in robotic-assisted procedures, with the Monarch system enabling minimally invasive access to hard-to-reach lung nodules, while also working on bringing its OTTAVA Robotic Surgical System to the market.
The Robot Report | 3 Jun, 2025
Netflix got the first and only interview with the chief suspect of the Tylenol murders by promising to treat him as a human being
- James Lewis, the chief suspect in the Tylenol murders, gave his first and only full interview in Netflix's 'Cold Case: The Tylenol Murders' where he denied the charges and spoke about the allegations against him.
- Lewis was accused of distributing cyanide-laced Tylenol in 1982, which led to the introduction of tamper seals in pharmaceutical products. He served time in prison for writing a ransom letter to Johnson & Johnson.
- Netflix's docuseries also includes interviews with family members of the victims, shedding light on the impact of the Tylenol murders in Chicago in 1982.
- The filmmakers earned Lewis' trust by promising to treat him as a human being during the interview, with producer Molly Forrester playing a key role in convincing him to participate.
Insider | 27 May, 2025
AI ain't B2B if OpenAI is to be believed
- OpenAI is shifting its focus towards consumers, indicating that AI is more likely to enter enterprises through end-users rather than traditional B2B sales strategies.
- New technologies typically infiltrate enterprises via front-door B2B sales facilitated by business leaders or through a back-door approach where end-users demand to use personal life technologies at work.
- OpenAI recently appointed consumer-focused executives and invested in projects involving high-profile figures like Jony Ive to enhance its consumer AI offerings.
- Consumer AI applications are typically used for lower-stakes tasks, while enterprise AI implementations often focus on efficiency gains in mundane tasks.
- AI usage in industries like law and finance is proving beneficial for tasks such as document summarization and data extraction.
- Despite AI advancements, top-down AI mandates in enterprises have not consistently delivered expected returns on investment, leading companies like Johnson and Johnson to refocus on proven value-driving initiatives.
- There are challenges in large organizations with AI implementations backfiring, leading to a reconsideration of AI's role in certain operations.
- Concerns exist around entrusting AI with critical tasks in sectors like banking and healthcare, where even minor errors can have significant consequences.
- The future of AI in enterprises is expected to be driven by employees who integrate AI into their workflows, with IT departments handling issues related to misuse and vendors providing necessary controls.
- Generative AI is likely to become more prevalent in businesses through employee adoption rather than formal B2B sales approaches.
The Register | 25 May, 2025
Radha Basu, CEO and Founder of iMerit – Interview Series
- Radha Basu, Founder and CEO of iMerit, has a strong background in technology and entrepreneurship, having worked at HP and Support.com before founding iMerit in 2012.
- iMerit provides AI data solutions using a combination of automation and human annotation to ensure high-quality data labeling and model fine-tuning at scale.
- Radha started iMerit to uplift marginalized youth by providing them with career opportunities in AI and technology.
- iMerit works with over 200 clients, including tech giants like eBay and Johnson & Johnson, and specializes in sectors like autonomous vehicles and medical AI.
- The company's growth journey involved partnering with clients from early experiments to large-scale production, gaining insights into scaling AI in real-world applications.
- iMerit faces unique data challenges in autonomous vehicles, medical AI, and GenAI tuning, focusing on data quality, exception handling, and ensuring safety and privacy.
- They believe in combining human intelligence with robotics to improve AI performance, emphasizing the importance of Human-in-the-Loop practices in AI development and deployment.
- The Ango Hub platform by iMerit blends automation with human-in-the-loop expertise to enhance data quality and model performance in production AI systems.
- iMerit stays ahead by launching the Ango Hub Deep Reasoning Lab for Generative AI tuning and developing chain-of-thought reasoning, ensuring model accuracy and coherence.
- Expert-in-the-Loop approach at iMerit involves human experts validating and refining automated system outputs to advance AI into production with high quality and reliability.
Unite | 21 May, 2025
S&P out of Red for ‘25
- The S&P 500 rose, putting it in positive territory for the year, amid easing U.S.-China trade tensions.
- The Dow Jones Industrials faced a decline on Tuesday due to a 16% drop in UnitedHealth.
- The NASDAQ Composite saw an increase of 1.6% to 19,010.09 points, with Nvidia's shares rising by 6%.
- Other highlights include Johnson & Johnson's stock performance, a proposed rule from CMS affecting its Darzalex Faspro therapy, the consumer price index, and changes in Treasury, oil, and gold prices.
Baystreet | 14 May, 2025
Stocks Look to Extend Streak
- S&P 500 remained flat as investors processed a softer-than-expected inflation report and aimed to continue the previous session's gains.
- Dow Jones dropped 117.48 points to 42,292.62, while NASDAQ climbed 213.76 points to 18,922.10.
- Johnson & Johnson's stock fell nearly 2% after CMS proposed a rule affecting its therapy. Consumer Price Index rose 2.3% annually in April, slightly below expectations.
- Market rallied Monday after U.S. and China agreed to reduce tariffs, easing concerns of a trade war. Treasury yields rose slightly, while oil prices increased to $62.74 U.S. a barrel.
Baystreet | 13 May, 2025
Invest in This ETF for Safety and Dividends
- Consider investing in the ProShares S&P 500 Dividend Aristocrats ETF (CBOE:NOBL) for safety and dividends.
- The ETF yields 2.2% and has averaged a beta value of 0.88, making it relatively less volatile than the market.
- It includes companies that have been increasing dividend payments for 25 years or more, focusing on strong fundamental businesses like AbbVie, Coca-Cola, and Johnson & Johnson.
- Over the past five years, the ETF has risen by more than 50%, offering total returns around 70% when factoring in dividends, suitable for long-term investors.
Baystreet | 12 May, 2025
The MedTech Company With a Waiting List to Invest
- FastWave Medical closed a $19 million investment round in less than a month, with an oversubscribed raise and a waitlist.
- The company focuses on intravascular lithotripsy (IVL) technologies for vascular care, targeting a market with a single incumbent, Johnson & Johnson.
- IVL is a minimally invasive therapy using sonic pressure waves to treat calcified cardiovascular diseases, offering a safer alternative to high-risk tools.
- FastWave's IVL devices aim to be more precise, efficient, and effective in managing arterial disease, with rapid clinical adoption and promising results.
- Following a successful first-in-human study in Mexico, FastWave achieved a 100% success rate, low complications, and impressive outcomes in treating blockages.
- The company holds 7 patents, proprietary technology, and a strong leadership team with proven experience in the medical technology sector.
- FastWave has raised over $40 million from various investors, including physician-led investors, validating its potential in the medtech market.
- The company plans to conduct more clinical studies, obtain regulatory approvals, and launch commercially in 2026, attracting significant interest from investors.
- FastWave Medical offers a high-upside opportunity in medtech, supported by clinical proof, commercial viability, and strong market interest.
Gritdaily | 1 May, 2025
Three Cheap Stocks: Skechers, J&J, and P&G
- Skechers (SKX) stock tumbles after posting quarterly results, facing macroeconomic uncertainty due to global trade policies.
- Johnson & Johnson (JNJ) risks re-testing the low in the weeks ahead, forecasts $400 million cost from newly imposed tariffs.
- P&G (PG) slumps to $160 support price, cuts profit guidance in fiscal third quarter report.
- P&G will rely on attractive branding and innovation to offset fall in retail traffic.
Baystreet | 29 Apr, 2025
Powered by
Johnson & Johnson Subsidiaries
Janssen Pharmaceuticals
4.2
• 34 reviews
Johnson & Johnson Medical
4.4
• 27 reviews
Johnson & Johnson Surgical Vision
3.0
• 17 reviews
Janssen
3.4
• 12 reviews
Johnson & Johnson Vision Care
4.1
• 12 reviews
Ethicon
4.1
• 11 reviews
Report error
Johnson & Johnson Offices
Compare Johnson & Johnson with
Dr Lal PathLabs
4.2
Pacific BPO
3.4
Thyrocare Technologies
3.6
Advantmed
4.3
Metropolis Healthcare
4.0
GE Healthcare
4.0
Baxter International
3.9
Redcliffe Labs
4.0
Columbia Asia
4.5
Care Hospital
4.2
Nephroplus
3.9
Philips Innovation Campus
3.7
HLL Lifecare
3.7
Aster Dm Healthcare
3.7
Krsnaa Diagnostics
3.7
Herbalife International
3.9
Shalby Hospitals
4.1
Healthians
3.4
Siemens Healthineers
4.0
Kauvery Hospital
4.0
Edit your company information by claiming this page
Contribute & help others!
You can choose to be anonymous
Companies Similar to Johnson & Johnson
GeBBS Healthcare Solutions
Financial Services, Healthcare
3.7
• 2.9k reviews
UnitedHealth
Healthcare
4.0
• 2.7k reviews
Paras Hospital
Healthcare
4.4
• 2.3k reviews
Dr Lal PathLabs
Healthcare
4.2
• 1.7k reviews
Pacific BPO
BPO/KPO, Healthcare, IT Services & Consulting
3.4
• 1.1k reviews
Thyrocare Technologies
Beauty & Wellness, Healthcare
3.6
• 1k reviews
Advantmed
Healthcare
4.3
• 937 reviews
Metropolis Healthcare
Healthcare / Pharma, Healthcare
4.0
• 910 reviews
GE Healthcare
Healthcare
4.0
• 812 reviews
Baxter International
Medical Equipment, Healthcare, Pharma
3.9
• 694 reviews
Redcliffe Labs
Fitness & Wellness, Healthcare
4.0
• 620 reviews
Columbia Asia
Healthcare
4.5
• 597 reviews
Johnson & Johnson FAQs
When was Johnson & Johnson founded?
Johnson & Johnson was founded in 1957. The company has been operating for 68 years primarily in the Healthcare sector.
Where is the Johnson & Johnson headquarters located?
Johnson & Johnson is headquartered in New Brunswick, New Jersey and has an office in Mumbai.
How many employees does Johnson & Johnson have in India?
Johnson & Johnson currently has more than 3,000+ employees in India. Sales & Business Development department appears to have the highest employee count in Johnson & Johnson based on the number of reviews submitted on AmbitionBox.
Does Johnson & Johnson have good work-life balance?
Johnson & Johnson has a Work-Life Balance Rating of 3.9 out of 5 based on 1,400+ employee reviews on AmbitionBox. 78% employees rated Johnson & Johnson 4 or above, while 22% employees rated it 3 or below on work-life balance. This indicates that the majority of employees feel a generally balanced work-life experience, with some opportunities for improvement based on the feedback. We encourage you to read Johnson & Johnson work-life balance reviews for more details.
Is Johnson & Johnson good for career growth?
Career growth at Johnson & Johnson is rated as moderate, with a promotions and appraisal rating of 3.3. 22% employees rated Johnson & Johnson 3 or below, while 78% employees rated it 4 or above on promotions / appraisal. This rating suggests that while some employees view growth opportunities favorably, there is scope for improvement based on employee feedback. We recommend reading Johnson & Johnson promotions / appraisals reviews for more detailed insights.
What are the pros and cons of working in Johnson & Johnson?
Working at Johnson & Johnson comes with several advantages and disadvantages. It is highly rated for company culture, salary & benefits and skill development. However, it is poorly rated for promotions / appraisal and job security, based on 1,400+ employee reviews on AmbitionBox.
Stay ahead in your career. Get AmbitionBox app
Trusted by over 1.5 Crore job seekers to find their right fit company
80 Lakh+
Reviews
10L+
Interviews
4 Crore+
Salaries
1.5 Cr+
Users
Contribute to help millions
AmbitionBox Awards
Get AmbitionBox app
Made with ❤️ in India. Trademarks belong to their respective owners. All rights reserved © 2025 Info Edge (India) Ltd.
Follow Us
